ABBOTT INDIA LIMITED

2024 saw significant advancements in diabetes technology, including Abbott's OTC CGM Lingo, Roche's AI-powered Accu-Chek SmartGuide, Dexcom's direct-to-watch G7 CGM, a partnership between Abbott and Medtronic, and Tandem's launch of the miniature Mobi insulin pump.

FDA grants de novo classification to Onward's ARC-EX, the first non-invasive spinal cord stimulator for SCI patients. ARC-EX met trial endpoints, showing improved strength, function, and quality of life. Onward plans European approval in 2025.

Abbott completed the first in-human leadless left bundle branch area pacing (LBBAP) procedures using the AVEIR Conduction System Pacing (CSP) leadless pacemaker system, offering a new treatment option for slower-than-normal heart rhythms. The study evaluates acute safety and performance of the AVEIR CSP system, combining conduction system and leadless pacing technologies. The FDA granted Breakthrough Device Designation for Abbott's AVEIR CSP system for LBBAP.

Nano-biotechnology revolutionizes healthcare with precise diagnostics, advanced drug delivery, and innovative therapies. The market, valued at USD 157.5 billion in 2023, is projected to grow at a CAGR of 9.3% to surpass USD 421.5 billion by 2034, driven by chronic disease management and innovations in personalized medicine and AI integration.

Dexcom launched a generative AI feature for its glucose sensors, analyzing health data for personalized tips on diet, exercise, and sleep. The feature is based on Google Cloud's Vertex AI and Gemini models, with plans for more AI-powered features. The FDA is exploring regulation of generative AI in medical devices.

Abbott's AVEIR™ Conduction System Pacing (CSP) leadless pacemaker system, designed for left bundle branch area pacing, received FDA Breakthrough Device Designation. The system aims to mimic natural heart beats, offering a new treatment for slow heart rhythms, with potential benefits over traditional pacemakers.

The Global Nano-Biotechnology Market, valued at $157.5 billion in 2023, is projected to reach $421.5 billion by 2034 with a CAGR of 9.3%, driven by advancements in drug delivery, diagnostics, imaging, and tissue engineering. Key drivers include precision medicine, targeted therapies, and AI integration. Challenges include high development costs and regulatory hurdles, but opportunities exist in emerging markets. North America leads, followed by Europe and Asia-Pacific. Major players include Johnson & Johnson, Abbott, and Novartis.

This episode of Diabetes Dialogue recaps CGM updates from Medtronic, Dexcom, Abbott, and Senseonics, marking the 25th anniversary of the first FDA-approved CGM. It covers historical context and 2024 advancements, including Medtronic's Simplera, Dexcom's Stelo, Abbott's Libre Rio, and Senseonics' 365-day Eversense.

Insomnia market report forecasts growth from 2020 to 2034, driven by increasing prevalence, awareness, and emerging therapies like Seltorexant and TS-142. Challenges include high treatment costs and patient non-compliance, with unmet needs for long-term solutions with minimal side effects.